PE20140926A1 - Combinacion anti-retroviral - Google Patents

Combinacion anti-retroviral

Info

Publication number
PE20140926A1
PE20140926A1 PE2013001497A PE2013001497A PE20140926A1 PE 20140926 A1 PE20140926 A1 PE 20140926A1 PE 2013001497 A PE2013001497 A PE 2013001497A PE 2013001497 A PE2013001497 A PE 2013001497A PE 20140926 A1 PE20140926 A1 PE 20140926A1
Authority
PE
Peru
Prior art keywords
refers
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
water
Prior art date
Application number
PE2013001497A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of PE20140926A1 publication Critical patent/PE20140926A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04Particle-shaped
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25Component parts, details or accessories; Auxiliary operations
    • B29C48/78Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83Heating or cooling the cylinders
    • B29C48/832Heating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA FORMA DE DOSIFICACION SOLIDA QUE CONTIENE: I) UN PRIMER GRANULO QUE COMPRENDE HIDRATO DE RITONAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE Y UN POLIMERO INSOLUBLE EN AGUA Y/O UN POLIMERO SOLUBLE EN AGUA; II) UN SEGUNDO GRANULO QUE COMPRENDE HIDRATO DE DARUNAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE. SE REFIERE TAMBIEN A UN METODO DE PREPARACION DE DICHA COMPOSICION FARMACEUTICA, SIENDO DE UTILIDAD EN EL TRATAMIENTO DEL VIH O SIDA
PE2013001497A 2007-12-24 2008-12-24 Combinacion anti-retroviral PE20140926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
PE20140926A1 true PE20140926A1 (es) 2014-08-06

Family

ID=54289250

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008002186A PE20091530A1 (es) 2007-12-24 2008-12-24 Combinacion anti-retroviral
PE2013001497A PE20140926A1 (es) 2007-12-24 2008-12-24 Combinacion anti-retroviral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008002186A PE20091530A1 (es) 2007-12-24 2008-12-24 Combinacion anti-retroviral

Country Status (20)

Country Link
US (1) US9339470B2 (es)
EP (2) EP2505193B1 (es)
JP (2) JP2011507940A (es)
CN (2) CN101925350B (es)
AP (2) AP2013007064A0 (es)
AT (1) ATE555778T1 (es)
AU (1) AU2008339633A1 (es)
BR (1) BRPI0819534A2 (es)
CA (1) CA2710605C (es)
DK (1) DK2242482T3 (es)
ES (2) ES2385819T3 (es)
GT (1) GT200800303A (es)
HK (1) HK1149905A1 (es)
JO (2) JO2814B1 (es)
MX (1) MX2010007083A (es)
PA (1) PA8809601A1 (es)
PE (2) PE20091530A1 (es)
RU (2) RU2531089C2 (es)
WO (1) WO2009081174A2 (es)
ZA (1) ZA201004505B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
EP2528923B1 (en) 2010-01-28 2014-07-30 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
US20130317040A1 (en) * 2010-12-22 2013-11-28 The Feinstein Institute Of Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
RS56667B1 (sr) * 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Kombinovane formulacije darunavira
US20140142174A1 (en) * 2011-07-07 2014-05-22 Urbain Alfons C. Delaet Darunavir formulations
JP6314131B2 (ja) * 2012-05-03 2018-04-18 シプラ・リミテッド 抗レトロウイルス組成物
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱(Emtricitabine)、替諾福韋(Tenofovir)、地瑞那韋(Darunavir)及利托那韋(Ritonavir)之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
US11045423B2 (en) * 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技(杭州)有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
WO1990007119A1 (en) 1988-12-20 1990-06-28 Immunodiagnostics, Inc. Synthetic hiv-like peptides, their compositions and uses
AU4810490A (en) 1988-12-20 1990-07-10 Mawzones Developments Limited Focussing device for a microwave antenna
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
ATE417836T1 (de) 1992-12-29 2009-01-15 Abbott Lab Verfahren und intermediate zur herstellung von retroviralen proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
RU2275361C3 (ru) 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
ES2313394T3 (es) * 2004-07-08 2009-03-01 Tibotec Pharmaceuticals Ltd. Combinacion de transcriptasa inversa anti-hiv e inhibidores de proteasa.
EP1814547A1 (en) * 2004-11-16 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2006325404B2 (en) 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral

Also Published As

Publication number Publication date
WO2009081174A2 (en) 2009-07-02
JP2015007071A (ja) 2015-01-15
CA2710605A1 (en) 2009-07-02
HK1149905A1 (en) 2011-10-21
CN103638032A (zh) 2014-03-19
ES2385819T3 (es) 2012-08-01
RU2010131006A (ru) 2012-02-10
AP2013007064A0 (en) 2013-08-31
ZA201004505B (en) 2013-05-29
US20110008429A1 (en) 2011-01-13
MX2010007083A (es) 2010-10-20
JO2814B1 (en) 2014-09-15
US9339470B2 (en) 2016-05-17
CA2710605C (en) 2017-05-02
WO2009081174A3 (en) 2009-08-27
JP2011507940A (ja) 2011-03-10
GT200800303A (es) 2009-09-18
AU2008339633A1 (en) 2009-07-02
EP2505193B1 (en) 2018-05-02
PE20091530A1 (es) 2009-09-25
RU2014111723A (ru) 2015-10-10
ES2674730T3 (es) 2018-07-03
EP2242482B1 (en) 2012-05-02
RU2675831C2 (ru) 2018-12-25
JO3376B1 (ar) 2019-03-13
RU2531089C2 (ru) 2014-10-20
AP2010005325A0 (en) 2010-08-31
CN101925350A (zh) 2010-12-22
EP2505193A1 (en) 2012-10-03
ATE555778T1 (de) 2012-05-15
BRPI0819534A2 (pt) 2015-05-26
CN101925350B (zh) 2014-04-30
EP2242482A2 (en) 2010-10-27
PA8809601A1 (es) 2009-07-23
DK2242482T3 (da) 2012-08-06
AP2855A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
PE20140926A1 (es) Combinacion anti-retroviral
MY187047A (en) Selective pyy compounds and uses thereof
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
WO2010084115A3 (en) Antiviral agents
WO2009055006A8 (en) Deuterated darunavir
PE20080422A1 (es) Composicion solida antirretroviral de administracion oral
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
PH12017500724A1 (en) Carbazole derivatives
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
CL2008000746A1 (es) Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
IN2013MU02911A (es)
NZ584968A (en) Novel antiretroviral combination comprising ritonavir and atazanavir
WO2010127272A3 (en) Hydroxyethylamino sulfonamide derivatives
AR067499A1 (es) Composicion farmaceutica estable que comprende una sal de vinflunina hidrosoluble
EA201891860A1 (ru) Фармацевтическая композиция пролонгированного высвобождения, содержащая цистеамин или его соли
MA39304A1 (fr) Formulations topiques d'héparine
AR098028A1 (es) Ácido 4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxiacético para su uso en la prevención o el tratamiento de la lesión renal aguda
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
RU2016147455A (ru) Способ лечения кожных проявлений склеродермии

Legal Events

Date Code Title Description
FC Refusal